Radiopharmaceutical Supply – Tc-99m Sestamibi

The contract is for the supply of non-highly enriched uranium derived Tc-99m Sestamibi, a radiopharmaceutical used in myocardial perfusion imaging, encompassing full synthesis, quality control, and timely delivery to ensure clinical readiness. The work is scoped as a subcontract under the Department of Veterans Affairs, managed by the 255-NETWORK Contract Office 15, with compliance required to meet all regulatory and safety standards for radiopharmaceutical production and handling. All materials must be derived from non-HEU sources to align with federal non-proliferation policies, and the supplier must guarantee consistent purity, potency, and sterility throughout the production and transportation process. The product must be delivered on a scheduled basis to support diagnostic imaging needs at VA medical facilities. The solicitation was posted on May 7, 2026, with a firm response deadline of May 15, 2026, at 12:00 PM, indicating a short turnaround for qualified vendors to submit proposals. The North American Industry Classification System code 325412 applies, confirming this is a pharmaceutical preparation activity. There is no set-aside designation specified, meaning any eligible contractor may respond regardless of business size or ownership characteristics. Performance location details are not provided, suggesting delivery may be required to multiple VA sites across the United States, and the contractor must manage logistics to ensure radiopharmaceuticals arrive within their short half-life window. The contract requires adherence to strict quality assurance protocols and may include penalties for delayed or non-compliant deliveries.